Myelofibrosis Secondary to Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Prognostic Model
Predicts survival in post-PV and post-ET patients with secondary myelofibrosis.
Advice
- Use risk categories and median survival estimates to tailor management plans and guide goals-of-care discussions with patients.
- Patients within intermediate-2 and high risk categories, particularly younger individuals with good functional status, may benefit from allogeneic stem cell transplantation.
- Low-risk individuals may be suited for a more conservative treatment approach.
- Do not base management decisions solely on these results; integrate them with clinical judgment, specialist consultations, and patient preferences.